Fort Worth-based NanOlogy LLC, a clinical-stage pharmaceutical development company, says it has enrolled its first patient in a Phase 2 clinical trial of its “NanoPac sterile suspension” method of chemotherapy for treating ovarian cancer.
NanoPac will be evaluated for safety and efficacy after its “instillation” following surgery to remove as much of the tumor as possible. The company says the “sterile suspension has been designed to be injected directly into tumors, where studies have demonstrated the nanoparticles remain and slowly release for four weeks, resulting in prolonged local exposure.”
Ovarian cancer is newly diagnosed in more than 22,000 women annually, NanOlogy says, and is the fifth-leading cause of cancer-related deaths in women.
Dr. Gere diZerega, NanOlogy’s vice president of medical affairs, said in a news release that the company is trying to prove that NanoPac will “effectively treat the cancer with … no contribution to systemic adverse effects.”
NanOlogy was formed by DFB Pharmaceuticals LLL of Fort Worth, Kansas-based CritiTech Inc., and US Biotest Inc. in California to finance and develop the NanoPac treatment. It has an extensive clinical development program underway for NanoPac, including trials for ovarian cancer, prostate cancer, and pancreatic cancer.